Equities

Neola Medical AB

NEOLA:STO

Neola Medical AB

Actions
Health CareMedical Equipment and Services
  • Price (SEK)2.54
  • Today's Change-0.06 / -2.31%
  • Shares traded290.00
  • 1 Year change+89.55%
  • Beta1.1023
Data delayed at least 15 minutes, as of Sep 23 2024 09:33 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Neola Medical AB, formerly GPX Medical AB is a Sweden-based company that is involved in development of medical instruments. The Company's business concept is to commercialize the Company's medical technology product for continuous lung monitoring based on the patented GASMAS (Gas in Scattering Media Absorption Spectroscopy) technology. Neola Medical's technology equipment aims for continuous monitoring of the lungs of premature babies. The primary purpose of Neola Medical is to support neonatal intensive care with NEOLA, a medical device that can offer continuous lung monitoring and real-time alerts about life-threatening complications using new technology that measures lung volume changes and oxygen concentration.

  • Revenue in SEK (TTM)0.00
  • Net income in SEK-9.47m
  • Incorporated2016
  • Employees7.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
BBS-Bioactive Bone Substitutes Oyj0.00-39.56m101.60m----1.16-----0.2926-0.29260.000.26470.00-------32.71-25.12-38.23-28.54-----------28.790.482-------12.64------
Observe Medical ASA-97.07bn-97.07bn105.31m5.00--0.6921----------0.5635-----------32.60---49.80--32.83---256.250.193--0.3425--43.14204.81-18.82--32.69--
Iconovo AB6.10m-39.03m106.33m29.00--0.8659--17.44-3.01-3.010.45267.710.0434--1.04210,251.40-27.76-25.43-31.28-28.24323.68134.57-640.15-215.16----0.0669---58.65-9.884.71--34.70--
Redsense Medical AB (publ)23.77m-3.98m108.54m5.00--3.38--4.57-0.2871-0.28711.651.950.75247.584.184,754,400.00-12.58-18.66-14.51-20.9920.47-2.72-16.72-46.284.00-89.340.00--74.1128.9448.47---23.62--
Episurf Medical AB12.10m-84.60m111.45m26.00--0.9476--9.21-0.2429-0.24290.03470.18070.0839--6.21432,142.80-58.81-47.46-67.73-52.01-----700.83-1,019.296.11--0.0321--53.6219.78-22.64---0.4158--
Luxbright AB4.20m-22.23m114.94m10.00--3.86--27.35-0.24-0.240.04540.26410.104--4.14420,270.00-55.02-61.39-62.23-70.36-134.43-577.85-528.90-2,529.110.7743-4,539.470.0084--55.58---20.07------
Glycorex Transplantation AB (publ)31.03m-27.83m118.94m15.00--3.25--3.83-0.3768-0.37680.42010.51860.4120.83823.691,348,913.00-36.96-11.30-46.32-13.1782.9191.60-89.70-33.241.09-71.860.2084---17.04-2.15-254.06---0.5593--
BibbInstruments AB0.00-11.84m124.41m4.00--3.60-----0.4417-0.44170.001.180.00-------31.46-39.57-33.52-42.71--59.36---8,032.404.34--0.00------2.72---1.94--
Phase Holographic Imaging PHI AB9.12m-21.81m155.06m17.00------17.00-0.8819-0.88190.3689-0.02730.23730.65981.18---56.73-62.04-88.25-79.6471.0663.16-239.04-328.500.1916-5.611.04--6.1617.9612.98--21.19--
Vo2 Cap Holding AB (publ)344.05m-3.18m162.68m95.00--0.70943.670.4729-0.0594-0.05946.494.030.7088--7.973,340,253.00-0.6554-0.2564-0.8674-0.383935.8423.36-0.9246-0.2409--0.32010.1362---26.0985.65-57.92---17.96--
Immunovia AB (publ)885.00k-116.12m165.75m10.00--4.23--187.29-1.30-1.300.00990.21620.0071--14.3980,454.55-93.50-41.33-133.56-44.24-6,702.03-7,553.76-13,120.79-20,879.29--2.480.3064--37.5536.48-84.09---50.93--
Neola Medical AB0.00-9.47m182.39m7.00--2.47-----0.1508-0.15080.001.050.00----0.00-12.63-17.04-13.59-18.46--4,237.20---5,258.78----0.00------12.97--55.46--
Arcoma AB175.30m12.66m202.40m31.0015.993.5810.131.150.95980.959813.304.282.023.969.195,654,936.0014.611.1224.242.0137.8537.667.220.75681.2518.830.04070.0030.366.4134.81--22.75--
SpectraCure AB (publ)2.36m-21.18m213.69m13.00--1.81--90.39-0.218-0.2180.02431.210.0166--24.63157,600.00-14.82-12.75-15.91-13.62442.39195.30-895.85-494.40----0.0494---3.30--19.46------
Nanexa AB26.91m-66.68m213.72m19.00--2.46--7.94-0.6938-0.69380.24840.64110.2108-3.832.991,416,316.00-52.24-40.77-70.59-48.77118.7777.27-247.79-532.261.92--0.0174--925.42147.00-30.44--39.10--
Bactiquant A/S13.68m-22.05m252.25m----24.26--18.44-0.6558-0.65580.40640.29060.51012.945.06---82.23-41.26-92.65-47.16-24.3412.89-161.20-71.772.73-9.480.5326---0.689--7.62------
Data as of Sep 23 2024. Currency figures normalised to Neola Medical AB's reporting currency: Swedish Krona SEK

Institutional shareholders

0.02%Per cent of shares held by top holders
HolderShares% Held
FCG Fonder ABas of 30 Aug 202410.19k0.02%
Data from 30 Aug 2024 - 30 Aug 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.